Novartis ranks first in 2024 Access to Medicine Index The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration...

Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities...

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics Sandoz to acquire three established brands sold in more than 100 marketsAcquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its...

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access...

Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality 2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across...